Arcturus Therapeutics Holdings Inc (ARCT)
Arcturus Therapeutics Holdings Inc. is a healthcare company focused on messenger RNA medicines, with an emphasis on therapies for liver and respiratory rare diseases. Its technology platforms include STARR, a self-amplifying mRNA platform, and LUNAR, a lipid-mediated delivery system. The company’s development pipeline includes ARCT-032, also known as LUNAR-CF, a Phase 2 candidate for cystic fibrosis, and ARCT-810, or LUNAR-OTC, which is in Phase 2 development for ornithine transcarbamylase deficiency. Arcturus also develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19, along with ARCT-2138 for seasonal influenza and ARCT-2304 for pandemic influenza, both in Phase 1 clinical trials. Founded in 2013, the company is headquartered in San Diego, California. The listed security is common stock on the NASDAQ exchange under the symbol ARCT.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ARCT
|
$7.78
|
28.6% Upside
|
Undervalued
|
$20.60
|
240.5% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
-2.2x
|
0.9x
|
3.1x
|
169.7 M
|
-15.713 M
|
12.4%
|
92.0%
|
2.2
|
—
|
74.6%
|
